Search Results for: australia

Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma

He Jiankui

I’m sure many of you remember He Jiankui, the guy who made CRISPR babies. He ended up serving three years in jail in China. He seems to be trying for something of a comeback since his release. Were He Jiankui invitations a mistake? Some prestigious places have even invited him to give talks, which seemed […]

Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma Read More »

Grading my 21 stem cell & regenerative medicine predictions for 2021

stem-cell-crystal-ball-300x3001

The world of stem cell research and regenerative medicine is unpredictable but it’s fun to be a part of it and try to do predictions. Each year in late December or early January I make prognostications for the coming year for stem cell research and regenerative medicine. I made 21 such predictions for the current

Grading my 21 stem cell & regenerative medicine predictions for 2021 Read More »

Weekly reads: CRISPR’d marsupial, outpatient recovery post stem cell transplants, Parkinson’s, pubs

CRISPR'd baby opossums.

This edition of The Niche weekly reads has a bit more good news than usual including on stem cell transplants. It’s nice to see positive developments like some recipients of hematopoietic stem cell transplants being able to stay at home afterwards. Also, a reminder. You have until July 31 to enter our stem cell video

Weekly reads: CRISPR’d marsupial, outpatient recovery post stem cell transplants, Parkinson’s, pubs Read More »

21 Stem Cell Research & Regenerative Medicine 2021 Predictions

stem-cell-crystal-ball-300x3001

In any given field of biomedical science like stem cell research and regenerative medicine, it’s very useful if you can accurately predict the future. It seems, though, that predictions are far more difficult within the more exciting and rapidly-changing fields. The field of stem cells and regenerative medicine fits that bill. Past stem cell research

21 Stem Cell Research & Regenerative Medicine 2021 Predictions Read More »

Mesoblast stock hit on gloomy data on stem cells for COVID-19

mesoblast ceo dr silvio itescu

I’ve been closely following the arena of stem cells for COVID-19 since the pandemic broke including the efforts of Mesoblast. Mesoblast unlikely to meet primary endpoints in Phase III COVID trial Now, the firm got bad news as its DSMB reported that they are unlikely to meet the primary endpoint for their Phase III trial

Mesoblast stock hit on gloomy data on stem cells for COVID-19 Read More »

Cell therapy trials for COVID-19 accelerate & some early reports

MultiStem-Athersys-cell-therapy-COVID-19

Could various kinds of cell therapy help patients with COVID-19? A variety of cell therapies, mostly focused on mesenchymal stromal/stem cells (MSCs), have gotten cleared quickly in the U.S., China, and Israel and possibly other countries to be tested in patients with the novel coronavirus. I hope at least one proves helpful. It’s mostly a

Cell therapy trials for COVID-19 accelerate & some early reports Read More »